Investment case

how you can participate

Investment Case

Modiblast is an early phase company in the field of oncology at the verge of entering into clinical stages. By repurposing known substances, we have successfully de-risked very important issues like safety and tolerability. In an off-label use scenario, where a patient has received a full cycle of treatment, our approach has shown efficacy in the complete human biological system.

Compared to other ventures in the field of oncology, our strategy promises a faster path to approval and does not depend on a complex infrastructure like many of the cell therapies under development. Therefore, a relatively modest investment may make a large step towards approval.

To further de-risk the project, the planned proof-of-concept trial could be split into a dose escalation and a single arm extension part. Taken together, Modiblast is a very attractive investment opportunity with a relatively low initial valuation and immense upside potential within a comparably short time frame (possibly less than 5 years).